ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (21)
2020
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2019
-
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement
Oncologist, Vol. 24, Núm. 5, pp. 603-611
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
2014
-
Trastuzumab in small tumours and in elderly women
Cancer Treatment Reviews, Vol. 40, Núm. 1, pp. 41-47
2013
2011
-
Hormone-responsive breast cancer
Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
-
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447
-
Supportive care for patients with early breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42
2009
-
Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study
Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2007
-
Current controversies in the management of early breast cancer
Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384
-
Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos
Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 12, Núm. 4, pp. 279-283
-
Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies
Leukemia, Vol. 21, Núm. 7, pp. 1413-1422
-
The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials
Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774